AzTrials
AzTrials

Sudden Sensorineural Hearing LossNCT06355102

The Development of Tinnitus in Patients With SSNHL: Insights From fMRI and Metabolomics

An observational study of Sudden Sensorineural Hearing Loss and Tinnitus, run by The First Affiliated Hospital with Nanjing Medical University at 1 site in China.

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts
Official record

Search all trials

Trial summary

The goal of this clinical trial is to investigate the factors and mechanisms underlying tinnitus generation and chronification in patients with sudden sensorineural hearing loss (SSNHL) . Read more about this study

Who is it for?
Ages 18 to 65 yearsHealthy volunteers can take part
Conditions the study is for
Sudden Sensorineural Hearing Loss, Tinnitus
What is being tested?
Conventional treatment and care
How many people
90 participants
Where
1 siteChina
Study dates
15 Apr 2024to 31 Mar 2026
Phase
Observational

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Patients with SSNHL and individuals undergoing physical examination at the Department of Otolaryngology, the First Affiliated Hospital of Nanjing Medical University

Who may be able to join

  • Group of SSNHL with Tinnitus:
  • Age between 18 and 65 years old;
  • Meets the diagnostic criteria for SSNHL; untreated within 5 days after onset;
  • Presence of tinnitus;
  • Able to complete questionnaires independently and cooperate with fMRI and follow-up assessments.
  • Group of SSNHL without Tinnitus:
Show all 14Show fewer
  • Age between 18 and 65 years old;
  • Meets the diagnostic criteria for SSNHL; untreated within 5 days after onset;
  • Absence of tinnitus;
  • Able to complete questionnaires independently and cooperate with fMRI and follow-up assessments.
  • Healthy Control:
  • Age between 18 and 65 years old;
  • Normal hearing screening results;
  • Able to complete questionnaires independently and cooperate with fMRI and follow-up assessments.

Who cannot join

  • Previous diagnosis of otic organic diseases such as otitis media, cholesteatoma of the middle ear, Ménière's disease, acoustic neuroma, hereditary deafness, inner ear malformations, etc.; history of ear surgery; long-term exposure to noise; use of ototoxic drugs;
  • Presence of brain organic diseases such as cerebral infarction, brain tumor, or contraindications for functional magnetic resonance imaging (fMRI) during nuclear magnetic resonance (NMR) examination;
  • History of mental illness, including anxiety, depression, insomnia, etc.;
  • Individuals unable to cooperate due to severe mental factors.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

China1 site
  • Department of Otolaryngology, the First Affiliated Hospital, Nanjing Medical University

    Nanjing, Jiangsu, 210029

Other trials in China

About this study

Official title: The Generation and Chronicity of Tinnitus in Patients With Sudden Sensorineural Hearing Loss: Insights From fMRI and Serum Metabolomics Analysis

The goal of this clinical trial is to investigate the factors and mechanisms underlying tinnitus generation and chronification in patients with sudden sensorineural hearing loss (SSNHL) . The main questions it aims to answer are:

  • What are the peripheral and central influencing factors that contribute to tinnitus in patients with SSNHL?
  • Can serum metabolic biomarkers be identified to predict and monitor tinnitus prognosis in these patients?
Read more

Participants in this study will include patients with SSNHL and tinnitus, patients with SSNHL without tinnitus, and healthy subjects. They will be asked to undergo a series of assessments, including audiological tests, vestibular function examinations, and functional magnetic resonance imaging (fMRI). Additionally, blood samples will be collected for metabolomics analysis.

Investigators will compare the brain functional states and serum metabolite profiles of patients with SSNHL and tinnitus to those without tinnitus. Morever, tinnitus symptom characteristics, audiological outcomes, and brain functional states will be assessed during time.

Read the detailed description

The incidence rate of tinnitus is very high globally and shows an increasing trend year by year. Sudden sensorineural hearing loss (SSNHL) , a prevalent otolaryngological emergency, often coincides with tinnitus among its patient population. This condition can significantly impact individuals' interpersonal relationships, work performance, and daily functioning, ultimately leading to a diminished quality of life and even psychological disturbances, such as anxiety and depression. Consequently, it is imperative to expore the mechanisms underlying the emergence and chronicity of tinnitus following SSNHL, and to devise targeted intervention strategies aimed at preventing the chronicity of tinnitus.

This study aims to enroll 30 patients with SSNHL accompanied by tinnitus, 30 patients with SSNHL without tinnitus, and 30 healthy subjects. Investigators will record general demographic information, tinnitus symptom characteristics, audiological examinations, vestibular function tests, and other information for each group during the acute phase of SSNHL onset. Using functional magnetic resonance imaging (fMRI), investigators will compare the brain functional states of patients with SSNHL accompanied by tinnitus and those without tinnitus during the acute phase to investigate the peripheral influencing factors and central mechanisms of tinnitus production. Additionally, investigators will conduct metabolomics analysis to compare the serum metabolite profiles of these two patient groups to identify serum metabolic biomarkers and prognostic biomarkers for tinnitus in patients with SSNHL accompanied by tinnitus. Furthermore, this study will conduct follow-up assessments on the subjects at 1 month, 3 months, and 6 months after the onset of SSNHL, reviewing changes in their symptom characteristics, audiological examinations, and fMRI. At 6 months after the onset, patients will be divided into a tinnitus recovery group and a tinnitus non-recovery group based on their tinnitus recovery status. Investigators will compare the general demographic characteristics, audiological examinations, and brain functional MRI findings between the two groups to explore the role and mechanisms of brain plasticity changes in the recovery or chronicity of tinnitus in patients with SSNHL.

Being tested
Conventional treatment and care
Keywords
Sudden sensorineural hearing loss, Tinnitus chronicity, Functional magnetic resonance imaging, Metabolomics
Medical subject headings
Hearing Loss, Sudden, Tinnitus

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Conventional treatment and careOther

    Conventional treatment and care

Study groups in NCT06355102
Study groupRoleWhat they receive
SSNHL with TinnitusPatients diagnosed with sudden sensorineural hearing loss accompanied with acute occuring tinnitus symptoms.
Receives: Other: Conventional treatment and care
SSNHL without TinnitusPatients diagnosed with sudden sensorineural hearing loss without acute occuring tinnitus symptoms.
Receives: Other: Conventional treatment and care
Health ControlHealthy subjects with normal hearing and no tinnitus.
Receives: Other: Conventional treatment and care

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Brain function states

    Fractional amplitude of low-frequency fluctuation, regional homogeneity, and functional connection will be compared among different groups using fMRI. Morever, the connections between the default mode network (DMN), central executive network (CEN), and salience network (SN) will be assessed through fMRI.

    Measured: Acute phase (within 5 days after onset), 1 month, 3 months, and 6 months after onset

  2. Serum metabolomics

    Serum metabolic profiles and characteristics will be gained and compared in patients SSNHL with or with tinnitus, using LC-MS metabolomics technology.

    Measured: Acute phase (within 5 days after onset)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Apr 2024
  2. Study start15 Apr 2024
  3. Primary completion31 Dec 2025 (estimated)
  4. Study completion31 Mar 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
90 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06355102
Sponsor's protocol ID
2024-SR-116
Status last verified
Oct 2024
First submitted
12 Mar 2024
Last updated
9 Oct 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in